drugset / Trial / NCT01558011
Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study
Phase 2
Terminated
51 enrolled
National Health Research Institutes, Taiwan
Mackay Memorial Hospital · collabNational Cheng-Kung University Hospital · collabTaipei Veterans General Hospital, Taiwan · collabTri-Service General Hospital (TSGH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, non-comparative phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma.
Timeline
- Start
- 2012-03
- Primary completion
- 2014-10
- Completion
- 2015-12
Outcome
Outcome not reported
Stopped: “The budget issues.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 500 mg | — |
| Subject | Docetaxel | Small molecule | 20 mg | — |
| Subject | Oxaliplatin | Small molecule | 50 mg | — |